Selvita
Selvita offers comprehensive drug discovery and development services, including AI-driven drug discovery, structural biology, and assay development, with expertise in various therapeutic areas and specialized services.
Selvita Drug Discovery Services
Selvita offers comprehensive drug discovery services, leveraging advanced technologies such as AI-driven drug discovery. These services include structural biology, recombinant protein production, and assay development and screening. Selvita's capabilities in structural biology cover crystallography, fast-track crystallization, and crystallization screening services. In addition, their assay development and screening services feature high-throughput screening (HTS), high-content screening (HCS), cell painting service, biophysical platform, and fragment-based drug discovery.
Selvita Drug Development Services
Selvita provides an extensive range of drug development services for small molecules and biologics. Key offerings include method development, validation and transfer, raw materials and APIs quality control, cGMP batch release testing, and ICH stability testing and storage. For biologics, Selvita also offers quality control of drug substances, excipients, and drug products, along with analytical support in formulation development. These services ensure compliance with regulatory standards and enhance the efficiency of the drug development process.
Therapeutic Areas of Expertise at Selvita
Selvita has extensive expertise across multiple therapeutic areas, including oncology, infectious diseases, inflammation, fibrosis, neurosciences, and respiratory diseases. The company provides in vitro and in vivo pharmacology services, toxicology, and translational research to support the development of treatments in these areas. Selvita's proficiency in diverse therapeutic areas enables it to address a wide range of medical challenges and support the development of innovative therapies.
Selvita Collaboration with University of Oxford
Selvita collaborates with the University of Oxford to advance potential therapeutics for Parkinson's disease. This partnership exemplifies Selvita's commitment to scientific innovation and its efforts to develop treatments for neurodegenerative disorders. Through this collaboration, Selvita contributes its expertise in drug discovery and development to support the research and development of new therapeutic options.
Selvita Research Center and Acquisitions
Selvita has invested in a new research center, further expanding its capabilities in drug development and analytical services. Additionally, Selvita has expanded its drug development capabilities through the acquisition of PozLab. These strategic investments enhance Selvita's infrastructure and resource capacity, enabling the company to offer advanced scientific services and meet the growing demands of the pharmaceutical and biotechnology industries.